March 27, 2024
Osteopore (ASX:OSX) secures Singaporean-Vietnamese approvals
A range of Osteopore products are cleared for market as the regenerative medicine company looks to stamp its place in a fast-growing industry.
Tag: Health
March 25, 2024
Argenica (ASX:AGN) receives paediatric approval from FDA for infants therapeutic that aims to save lives
A Pediatric Disease Designation for Argenica’s therapeutic opens the post-clinical way for a priority review and path to market.
March 7, 2024
Immuron (ASX:IMC) looks toward pivotal Travelan trials
More positive Travelan results support progression toward Phase 3 clinical trials and a pivotal FDA registration.
February 12, 2024
Argenica (ASX:AGN) completes clinical manufacturing
Manufacturing of GMP grade ARG-007 is done, and the novel neurodegenerative therapeutic is ready for next month’s Phase 2 trials.
December 14, 2023
Argenica (ASX:AGN) mark the manufacturing milestone for clinical trials
A manufacturing milestone paves the way to begin Phase 2 clinical trials and towards pivotal Phase 3 and potential partnerships.
November 15, 2023
Argenica (ASX:AGN) granted Orphan Drug Designation by the FDA
An Orphan Designation opens up tax credits for clinical trials, user fee exemptions, and potentially seven years of market exclusivity.